Clinical Trial Update: Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SR57667B on 18F-Dopa PET imaging in patients with Parkinson disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SR57667B

Snippet

Sponsor: Sanofi | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED